drugset / Trial / NCT00349245
Dexmedetomidine vs. Remifentanil for Sedation During AFI
Phase 4
Completed
30 enrolled
The University of Texas Health Science Center, Houston
Hospira, now a wholly owned subsidiary of Pfizer · collab
RandomizedParallel-groupDouble-blind
Summary
The objective of this study is to determine the efficacy and safety of Dexmedetomidine, a selective alpha-2 adrenoceptor agonist, which has recently gained increased popularity for ICU and intraoperative sedation as a sedative during awake fiberoptic intubation, as compared to Remifentanil. The hypothesis is that Dexmedetomidine will provide at least equal if not better conditions (sedation and analgesia) required for awake fiberoptic intubation (Ramsay Sedation Scale 3) with less respiratory and cardiovascular adverse effects, as well as less recall than Remifentanil.
Timeline
- Start
- 2006-06
- Primary completion
- 2007-08
- Completion
- 2007-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexmedetomidine | Other / unclassified | — | — |
| Subject | Remifentanil | Small molecule | — | — |
Indications
No indication recorded.